Mineralocorticoid receptors are implicated in the initial steps of the cardiorenal damage induced by ethanol - Report - MDSpire

Mineralocorticoid receptors are implicated in the initial steps of the cardiorenal damage induced by ethanol

  • By

  • Thales M. H. Dourado

  • Gustavo F. Pimenta

  • Barbara M. Marchetti

  • Alessandra O. Silva

  • Carlos R. Tirapelli

  • June 23, 2026

  • 0 min

Share

Clinical Report: Mineralocorticoid Receptor Activation and Ethanol-Induced Injury

Overview

This study investigates the role of mineralocorticoid receptor (MR) activation in ethanol-induced cardiorenal injury.

Background

Ethanol consumption is linked to significant cardiorenal dysfunction, primarily through oxidative stress mechanisms. The activation of the renin-angiotensin-aldosterone system (RAAS) and subsequent MR activation are critical in mediating these effects.

Data Highlights

ParameterControlEthanolEthanol + MRA
Superoxide LevelsBaselineIncreasedPrevented
Hydrogen Peroxide (H2O2)Not DetectedIncreasedPrevented
Thromboxane (TX)B2BaselineIncreasedAbrogated
Prostaglandin (PGE)2BaselineIncreasedAbrogated

Key Findings

  • MR blockade with potassium canrenoate prevented increases in lipoperoxidation in ethanol-treated rats.
  • Superoxide levels were significantly elevated in the left ventricle of ethanol-treated rats but normalized with MR blockade.
  • Hydrogen peroxide levels increased in the renal cortex of ethanol-treated rats, which was prevented by MR antagonism.
  • Ethanol exposure led to elevated levels of thromboxane B2 and prostaglandin E2, both of which were abrogated by MR blockade.
  • The study highlights the role of MR in mediating oxidative stress during early ethanol-induced cardiorenal dysfunction.

Clinical Implications

Further research is warranted to explore the therapeutic potential of MR antagonists in clinical settings.

Conclusion

This study demonstrates that MR activation plays a role in ethanol-induced cardiorenal injury.

Related Resources & Content

  1. Frontiers in Cardiovascular Medicine, 2026 -- Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors
  2. Basic Research in Cardiology, 2024 -- Inter-organ Communication: Strategies and Targets for Cardioprotection and Neuroprotection
  3. Basic Research in Cardiology, 2015 -- Summary of the 2nd International Symposium on Innovations in Cardiovascular Research
  4. Journal of Cardiac Failure, 2026 -- Targeted Potassium Levels, Mineralocorticoid Receptor Antagonism, and Cardiovascular Outcomes
  5. American Heart Association, 2025 -- Alcohol Use and Cardiovascular Disease
  6. American College of Cardiology, 2026 -- Feature | Finerenone: Expanding Heart Failure Treatment
  7. KDIGO, 2026 -- Kidney disease guidance and outcomes with MR blockade
  8. Alcohol Use and Cardiovascular Disease - Professional Heart Daily | American Heart Association
  9. Feature | Finerenone: Expanding Heart Failure Treatment - American College of Cardiology
  10. https://kdigo.org/wp-content/uploads/2026/03/KDIGO-2026-Diabetes-and-CKD-Guideline-Update-Public-Review-Draft.pdf

Original Source(s)

Related Content